Whole genome sequencing not ready for prime time.
I agree that WGS is not ready for prime-time yet. Routine molecular testing--even for colon and lung in which there are more clear indications with respect to treatment--isn't truly ready. I'm not even mentioning the whole payment/reimbursement side.
It's interesting to me that there is so much professional and lay press regarding "personalized medicine" without practical considerations of quality, access, and cost.
Should pathologists and oncologists routinely obtain molecular or ancillary testing on lung or colon cancer? regardless of stage? histology? future treatment and cost considerations?
We should take the pathologic diagnosis and staging as a starting point to discuss with clinicians whether molecular testing is indicated and when it is needed (and who is going to pay and how much it will cost).